Morphic Holding, Inc.
DelistedCIK 1679363fmd_0NMBDCZ4718W82ENG35Z4A1Y84Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2018 to Jun 30, 2024, 26 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|
| Total revenues | 3 | 17 | 45 | 20 | 71 | 1 |
| Research and development | 23 | 54 | 74 | 88 | 102 | 140 |
| Operating income | (25) | (47) | (47) | (96) | (63) | (179) |
| Interest expense | 0 | – | – | – | – | – |
| Interest and investment income | 1 | 5 | 2 | 0 | 5 | 27 |
| Other non-operating income (expense) | 1 | 5 | 2 | 0 | 4 | 27 |
| Income before taxes | (24) | (42) | (46) | (96) | (59) | (152) |
| Income tax expense | 0 | 1 | (1) | 0 | 0 | 0 |
| Net income from continuing operations | (24) | (43) | (45) | (96) | (59) | (152) |
| Net income | (24) | (43) | (45) | (96) | (59) | (152) |